Torrent Pharma Q1 Review - DF On A Strong Footing; Making Inroads In Trade Generics: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Torrent Pharmaceuticals Ltd.’s Q1 FY22 performance was largely in line with our estimates.
Growth momentum in the domestic formulation business was offset by a muted showing in the U.S. business and a higher tax rate.
It continues to work on alternate site filings to lower the impact of U.S. Food and Drug Administration regulatory issues.
The branded generics segment in DF/Latin America/Germany is improving, with an ease in Covid-19 cases.
Torrent Pharma’s plan to make inroads into the trade generics segment would further boost growth opportunities in the DF segment.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.